1. Home
  2. EHAB vs PROK Comparison

EHAB vs PROK Comparison

Compare EHAB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhabit Inc.

EHAB

Enhabit Inc.

HOLD

Current Price

$9.53

Market Cap

403.5M

Sector

Health Care

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$2.25

Market Cap

417.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHAB
PROK
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
403.5M
417.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EHAB
PROK
Price
$9.53
$2.25
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$9.00
$6.25
AVG Volume (30 Days)
606.8K
1.4M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,047,800,000.00
$744,000.00
Revenue This Year
$4.95
$918.66
Revenue Next Year
$4.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.02
N/A
52 Week Low
$6.47
$0.46
52 Week High
$10.91
$7.13

Technical Indicators

Market Signals
Indicator
EHAB
PROK
Relative Strength Index (RSI) 70.29 41.28
Support Level $7.87 $2.04
Resistance Level $8.39 $2.25
Average True Range (ATR) 0.36 0.20
MACD 0.16 -0.00
Stochastic Oscillator 90.31 26.19

Price Performance

Historical Comparison
EHAB
PROK

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: